Immunotherapy expert Dr. David Oh explains how the immune system can be trained to recognize and fight prostate cancer. He outlines key immune players—dendritic cells and T cells—and describes how immunotherapies target different stages of their interaction with tumors. Oh highlights FDA-approved treatments such as Provenge, a vaccine made from a patient's own cells, and PD-1 checkpoint inhibitors for patients with specific genetic mutations like microsatellite instability. He also discusses potential autoimmune side effects and emphasizes the importance of genetic testing. Looking ahead, he introduces bispecific T-cell engagers, experimental therapies that physically link T cells to tumors, triggering an immune attack. These promising treatments offer new hope, especially for men with advanced, treatment-resistant prostate cancer. Recorded on 05/02/2025. (#40811)